RBC Capital initiated coverage of Ocular Therapeutix (OCUL) with an Outperform rating and $17 price target Checks with key opinion leaders give the firm confidence that long-acting TKIs are poised to take a chunk of the $15B anti-VEGF market and that the company’s formulation is “relatively de-risked.” With the wet AMD landscape already heading towards longer-acting therapy, the firm thinks Ocular is well-positioned to further advance this trend and capture about 10% market share, adds the analyst, who views shares as “currently undervalued.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCUL:
- Beam, Unity, Checkpoint, Inuvo, Ocular: Trending by Analysts
- Biotech Alert: Searches spiking for these stocks today
- Strategic Trial Adjustments and Efficiency Boost Ocular Therapeutix’s Prospects: A Buy Rating Justification
- Ocular Therapeutix initiated with a Buy at Needham
- Ocular Therapeutix: Strategic Developments and Revenue Growth Justify Buy Rating